This is a working overview of subcutaneous dosing, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
== Metabolism == Metabolic activation is required for PhIP to function as a mutagen. Therefore, the cancer risk posed by PhIP depends on the extent at which PhIP is metabolized. After absorption, PhIP is converted to a genotoxic metabolite in the liver by Phase I enzyme N-oxidation by Cytochrome P-450 1A2 (CYP1A2). PhIP can be further metabolized into a more potent metabolite through O-acetylation by hepatic or colonic N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2), or by sulfotransferases. However, PhIP may also undergo a detoxification pathway through Phase II conjugation reaction via UDP-glucuronosyltransferases (UGTs) to form N-glucuronide conjugates. PhIP's nitrenium ion intermediate is a powerful electrophile that has propensity to form C-8 guanine adducts with the DNA. In addition, some of these metabolic enzymes are inducible and have polymorphic variation. CYP1A2 displays a 40-fold variation in expression among humans and can be induced by smoking, diet, and chronic hepatitis. The expression of UGTs also displays inducibility; however, NATs do not. Individuals can be classified as either rapid or slow N-oxidizers and O-acetylators by assessing CYP1A2 and NAT2 activities. Individuals with the rapid phenotype of either CYP1A2 or NAT2 metabolize PhIP more effectively and are therefore at greater risk of PhIP's carcinogenic metabolite and could be at a higher risk of cancer.
==== London Bullion Market Association ==== In November 2020, the London Bullion Market Association wrote a letter to a number of countries with huge gold markets, including Dubai (United Arab Emirates), China, Singapore, South Africa, Russia, Japan, United States and others, laying out the standards regarding money laundering and other issues like where they sourced their gold. It also threatened that these countries could be blacklisted, if they failed to meet the regulatory standards. This was LBMA's first move to challenge the illegal or unethical production and trading of gold.
== Bioactivities == Salidroside was shown to improve glucose homeostasis and alleviate diabetic retinopathy in obese mice. The antioxidant, anti-inflammatory and neuroprotective effects of salidroside have also been reported.
conformation The three-dimensional spatial configuration of the atoms comprising a molecule or macromolecular structure. The conformation of a protein is the physical shape into which its polypeptide chains arrange themselves during protein folding, which is not necessarily rigid and may change with the protein's particular chemical environment.
The objectives of the Party of European Socialists, the European Parliament's social democratic bloc, are now "to pursue international aims in respect of the principles on which the European Union is based, namely principles of freedom, equality, solidarity, democracy, respect of Human Rights and Fundamental Freedoms, and respect for the Rule of Law." As a result, today the rallying cry of the French Revolution—Liberté, égalité, fraternité—is promoted as essential socialist values. To the left of the European Socialists at the European level is the Party of the European Left, a political party at the European level and an association of democratic socialist and communist parties in the European Union and other European countries. It was formed for the purposes of running in the 2004 European Parliament election. The European Left was founded on 8–9 May 2004 in Rome. Elected MEPs from member parties of the European Left sit in the European United Left–Nordic Green Left group in the European Parliament. The democratic socialist Left Party in Germany grew in popularity, as did popular dissatisfaction with the increasingly neoliberal policies of the Social Democratic Party of Germany after Gerhard Schröder's tenure as Chancellor, becoming the fourth biggest party in parliament in the general election on 27 September 2009. In 2008, the Progressive Party of Working People candidate Dimitris Christofias won a crucial presidential runoff in Cyprus, defeating his conservative rival with a majority of 53%.
Sources: en.wikipedia.org
Histatins are encoded by two genes, HTN1 and HTN3. The primary members include histatin 1 (38 amino acids), histatin 3 (32 amino acids), and histatin 5 (24 amino acids), with histatin 5 derived from proteolytic cleavage of histatin 3. Histatin 1 (UniProt ID: P15515) is notable for its phosphorylation at serine residues, which enhances its binding to hydroxyapatite in the acquired enamel pellicle.
== Early life, education and career == Moroder studied chemistry at the University of Padova, where he graduated 1965 in chemistry with the doctoral thesis on synthesis of S-peptide of ribonuclease A in the laboratory of Ernesto Scoffone at the Institute of Organic Chemistry. In 1968 he joined Klaus H. Hofmann's Group at the University of Pittsburgh to work on chemical synthesis of the peptidic adrenocorticotropic hormone and its derivatives. Moroder habilitated in 1971 at the University of Padova in Chemistry of Natural Products. 1975 he became a senior research fellow in the Department of Peptide Chemistry at the Max Planck Institute for Biochemistry (MPIB) in Martinsried headed by Erich Wünsch. Between 1991 and 2008 he was the head of the Laboratory of Bioorganic chemistry at the MPIB. Since 1994 he was an adjunct professor at the Technical University of Munich.
Neanderthal specimens vary in height from 147.5 to 177 cm (4 ft 10 in to 5 ft 10 in), with average male dimensions estimated at 165 cm (5 ft 5 in) and 75 kg (165 lb). While Neanderthal brain volume and ratio to body size averaged higher than any living human population — 1,640 cc (100 cu in) for males and 1,460 cc (89 cu in) for females — their brain organisation differed from modern humans in areas related to cognition and language, which could explain the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals maintained a low population and suffered inbreeding depression, which may have impeded their ability to progress technologically. They produced Mousterian stone tools (a Middle Palaeolithic industry) and possibly wore blankets and ponchos. They maintained and might have created fire. They predominantly ate whatever was abundant close to home, usually big game as well as plants and mushrooms. Neanderthals were frequently victims of major physical traumas and animal attacks. Examples of Palaeolithic art have been inconclusively attributed to Neanderthals, namely possible ornaments made from bird claws and feathers; collections of unusual objects including crystals and fossils; and engravings. Neanderthals buried their dead, but there is no clear indication that they believed in life after death.
Ginkgo biloba is a living fossil, with fossils recognisably related to modern ginkgo from the early Permian (Cisuralian), with likely oldest record being that of Trichopitys from the earliest Permian (Asselian) of France, over 290 million years old. The closest living relatives of the clade are the cycads, which share with the extant G. biloba the characteristic of motile sperm. Such plants with leaves that have more than four veins per segment have customarily been assigned to the taxon Ginkgo, while the taxon Baiera is used to classify those with fewer than four veins per segment. Sphenobaiera has been used for plants with a broadly wedge-shaped leaf that lacks a distinct leaf stem.
A superlens is a two or three-dimensional device that uses metamaterials, usually with negative refraction properties, to achieve resolution beyond the diffraction limit (ideally, infinite resolution). Such a behavior is enabled by the capability of double-negative materials to yield negative phase velocity. The diffraction limit is inherent in conventional optical devices or lenses.
Sources: en.wikipedia.org
=== Conversion to esters, amides, anhydrides === Widely practiced reactions convert carboxylic acids into esters, amides, carboxylate salts, acid chlorides, acid anhydrides, and alcohols. Their conversion to esters is widely used, e.g. in the production of polyesters. Likewise, carboxylic acids are converted into amides, but this conversion typically does not occur by direct reaction of the carboxylic acid and the amine. Instead esters are typical precursors to amides. The conversion of amino acids into peptides is a significant biochemical process that requires ATP. Converting a carboxylic acid to an amide is possible, but not straightforward. Instead of acting as a nucleophile, an amine will react as a base in the presence of a carboxylic acid to give the ammonium carboxylate salt. Heating the salt to above 100 °C will drive off water and lead to the formation of the amide. This method of synthesizing amides is industrially important, and has laboratory applications as well. In the presence of a strong acid catalyst, carboxylic acids can condense to form acid anhydrides. The condensation produces water, however, which can hydrolyze the anhydride back to the starting carboxylic acids. Thus, the formation of the anhydride via condensation is an equilibrium process. Under acid-catalyzed conditions, carboxylic acids will react with alcohols to form esters via the Fischer esterification reaction, which is also an equilibrium process. Alternatively, diazomethane can be used to convert an acid to an ester.
Thatcher wrote "I will not tolerate failure in this area" in the margin of the report and in the summer of 1982 a new committee was set up under Willie Whitelaw, only to come to much the same conclusion (The eventual solution, a "poll tax", was rejected both by the Green Paper and by Whitelaw's committee). Heseltine resisted demands by Leon Brittan, the Chief Secretary to the Treasury with whom he already enjoyed a somewhat antagonistic relationship, that central government have power to cap the spending of local authorities. He argued that the worst offenders were the large metropolitan counties (which, ironically, he had helped to create a decade earlier) and that the simplest solution was simply to abolish them. In the event, the 1983 manifesto, after Heseltine had moved to his next job, committed the Conservatives both to abolition of the metropolitan boroughs and to rate capping. When Heseltine objected after the election, Thatcher gave him "one of the most violent rebukes I have ever witnessed in Cabinet" according to Jim Prior, who believed that the issue helped fuel the hostility between Heseltine and Thatcher and Brittan, which would later exhibit itself as the Westland Affair. In opposition, in the late 1970s, Heseltine had been committed to reducing central government control over local government. In the 1980s, the opposite happened, with no less than 50 Acts of Parliament reducing the powers of local government. In Crick's view, although he opposed both rate capping and the poll tax, the overall trend towards centralisation was too strong for him to resist.
=== Fa–Fi === Leone N. Farrell (1904–1986). Canadian biochemist and microbiologist at Connaught Laboratories (Toronto) who discovered a way to isolate live virus in bulk quantities, sufficient for producing the polio vaccine. Richard D. Feinman (b. 1940). American biochemist and medical researcher at SUNY Downstate Medical Center, known for research on the Atkins Diet, and on application of thermodynamics to nutrition. David Sidney Feingold (1922–2019). American biochemist at the University of Pittsburgh known for research on carbohydrates. David Fell (b. 1947). British biochemist at Oxford Brookes University who has contributed to the development of systems biology. Author of Understanding the control of metabolism. John D. Ferry (1912–2002). Canadian-American biochemist at the University of Wisconsin–Madison noted for development of surgical products from blood plasma. Member Natl. Acad. Sci. USA. Alan Fersht FRS (b. 1943). British chemist and biochemist at the University of Cambridge, known for enzyme kinetics and protein folding. Foreign Associate Natl. Acad. Sci. USA. Edmond H. Fischer FRS (foreign member) (1920–2021). Swiss American biochemist at the University of Washington known for protein kinases and phosphatases. Nobel Prize in Physiology or Medicine (1992). Member Natl. Acad. Sci. USA.
== Interactions == Only in vitro interaction studies are available. In these, trifluridine used the concentrative nucleoside transporter 1 (CNT1) and equilibrative nucleoside transporters 1 (ENT1) and 2 (ENT2). Drugs that interact with these transporters could influence blood plasma concentrations of trifluridine. Being a thymidine phosphorylase inhibitor, trifluridine could also interact with substrates of this enzyme such as zidovudine. For the eye drops, trifluridine absorption is negligible, rendering interactions basically irrelevant.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.